Video Experimental Relacionado
Updated: Feb 24, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Antibióticos profilácticos en neumopatías crónicas pediátricas: equilibrio entre beneficio, resistencia y modelos de
Isaac Martin1,2, Valerie Waters2,3
1Division of Paediatric Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON , Canada.
Introduction:
Children with chronic suppurative or inflammatory lung diseases, including cystic fibrosis (CF), non-CF bronchiectasis (NCFB), chronic suppurative lung disease (CSLD), and primary ciliary dyskinesia (PCD), experience recurrent infection and persistent neutrophilic airway inflammation that together drive progressive lung injury. Prophylactic antibiotic strategies have therefore been explored to interrupt this infection - inflammation cycle, encompassing both pathogen-specific approaches and longer-term anti-exacerbation or immunomodulatory therapies.
Areas Covered:
We review clinical trials, observational studies, and guideline recommendations evaluating prophylactic antibiotic use in chronic pediatric lung disease. A targeted literature search using PubMed was conducted, focusing on macrolide and non-macrolide prophylactic strategies in children under 18 years of age, disease-specific outcomes, antimicrobial resistance, and stewardship considerations across pediatric respiratory disorders.
Expert Opinion:
Evidence supporting antibiotic prophylaxis varies substantially by disease and clinical context. We propose a framework for selective, time-limited use of prophylactic antibiotics, emphasizing individualized risk - benefit assessment, regular reassessment of efficacy, and integration within antimicrobial stewardship paradigms.
Más Videos Relacionados
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Videos de Conceptos Relacionados
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cystic Fibrosis: Management
Sinus disease and chronic...
COPD: Management Using Bronchodilators and Corticosteroids